News Quantified

RYTM – rhythm pharmaceuticals, inc. (US:NASDAQ)

Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says [Yahoo! Finance]

12/12

10:01 am

rytm

Low

Rhythm Pharmaceuticals (NASDAQ:RYTM) was given a new $141.00 price target on by analysts at Canaccord Genuity Group Inc..

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Citizens Jmp from $141.00 to $167.00. They now have a "market outperform" rating on the stock.

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}